Draig Therapeutics Stock

Draig Therapeutics is a clinical-stage biopharmaceutical company that develops investigational therapies for neuropsychiatric disorders. The company focuses on designing highly selective modulators of AMPA and GABA_A receptors to address conditions associated with disrupted brain signaling, including major depressive disorder. Its research pipeline includes drug candidates in clinical and preclinical development that aim to restore the balance of key neurotransmitter systems through targeted mechanisms of action. Draig Therapeutics conducts its research by combining expertise in neuroscience, drug discovery, and clinical development while working with patients and care partners to inform its programs. The company also advances scientific research through clinical studies and publications that evaluate the safety, tolerability, and therapeutic potential of its investigational treatments.